Authors: Dalle, Stephane; Costes, Safia; Quoyer, Julie; Bertrand, Gyslaine; Broca, Christophe

Source: Recent Patents on Endocrine, Metabolic & Immune Drug Discovery, Volume 1, Number 3, November 2007 , pp. 180-192(13)

Publisher: Bentham Science Publishers

Abstract:

Type 2 diabetes (T2D) is a heterogeneous disorder that is characterized by chronic hyperglycemia and its prevalence reaches epidemic proportions worldwide. T2D is characterized by a progressive loss of the first phase of insulin secretion in early stages of the disease. The origin of insulin secretion failure is still unknown. As hyperglycemia becomes chronic, pancreatic β-cell undergoes deterioration and destruction. β-Cell destruction by glucolipotoxic-mediated apoptosis and by proinflammatory cytokines actions is important etiological factor in the progression of the disease. The focus of this review is on the signaling pathways engaged by G-protein coupled receptors and tyrosine-kinase receptors which control β-cell function and survival through cell kinases (i.e., cAMP/PKA, IRS/PI3-kinase, and ERK1/2), and as well as on pathways implicated in β-cell dysfunction and death, among them glucotoxicity and lipotoxicity. A better knowledge of these pathways (and of their dysfunctions) will have significant implications for the prevention and management of T2D (patents and design of new drug targets for therapeutic approach), as well as for our general understanding of β-cell failure in this disease. Finally, the current and future molecular targets for designing innovative therapeutic agents with the aim to restore β-cell mass and insulin secretion are reviewed.

Keywords: Pancreatic β-cells; insulin secretion dysfunction; apoptosis; signaling pathways; glucotoxicity; lipotoxicity; therapeutic agents

Document Type: Research article

DOI: http://dx.doi.org/10.2174/187221407782409116

Publication date: 2007-11-01

More about this publication?

• Recent Patents on Endocrine, Metabolic & Immune Drug Discovery publishes review articles by experts on recent patents in the field of endocrine, metabolic and immune drug discovery e.g. on novel bioactive compounds, analogs & targets. A selection of important and recent patents in the field is also included in the journal. The journal is essential reading for all researchers involved in endocrine, metabolic and immune drug design and discovery.

Related content

• In this: publication
• By this: publisher
• In this Subject: Allergy & Immunology ,  Pharmacology
• By this author: Dalle, Stephane ;  Costes, Safia ;  Quoyer, Julie ;  Bertrand, Gyslaine ;  Broca, Christophe

Website © Publishing Technology. Article copyright remains with the publisher, society or author(s) as specified within the article.

• Terms and conditions
• Privacy policy
• Information for advertisers